88 related articles for article (PubMed ID: 28968952)
1. DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer.
Nieto-Jiménez C; Alcaraz-Sanabria A; Páez R; Pérez-Peña J; Corrales-Sánchez V; Pandiella A; Ocaña A
Oncotarget; 2017 Sep; 8(38):62834-62841. PubMed ID: 28968952
[TBL] [Abstract][Full Text] [Related]
2. Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors.
Pérez-Peña J; Alcaraz-Sanabria A; Nieto-Jiménez C; Páez R; Corrales-Sánchez V; Serrano-Oviedo L; Wali VB; Patwardhan GA; Amir E; Győrffy B; Pandiella A; Ocaña A
Oncotarget; 2017 Mar; 8(13):21733-21740. PubMed ID: 28423514
[TBL] [Abstract][Full Text] [Related]
3. Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors.
Martínez-Canales S; Cifuentes F; López De Rodas Gregorio M; Serrano-Oviedo L; Galán-Moya EM; Amir E; Pandiella A; Győrffy B; Ocaña A
PLoS One; 2017; 12(5):e0175128. PubMed ID: 28472085
[TBL] [Abstract][Full Text] [Related]
4. Genomic Correlates of DNA Damage in Breast Cancer Subtypes.
Cabañas Morafraile E; Pérez-Peña J; Fuentes-Antrás J; Manzano A; Pérez-Segura P; Pandiella A; Galán-Moya EM; Ocaña A
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33925616
[TBL] [Abstract][Full Text] [Related]
5. Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer.
Ocaña A; Pérez-Peña J; Díez-González L; Sánchez-Corrales V; Templeton A; Seruga B; Amir E; Pandiella A
Breast Cancer Res Treat; 2016 Feb; 156(1):1-8. PubMed ID: 26897635
[TBL] [Abstract][Full Text] [Related]
6. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.
Schwentner L; Wolters R; Koretz K; Wischnewsky MB; Kreienberg R; Rottscholl R; Wöckel A
Breast Cancer Res Treat; 2012 Apr; 132(3):1073-80. PubMed ID: 22205141
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of TMED2 is an unfavorable prognostic factor in patients with breast cancer.
Lin X; Liu J; Hu SF; Hu X
Cancer Manag Res; 2019; 11():2203-2214. PubMed ID: 31114314
[No Abstract] [Full Text] [Related]
8. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.
Bartlett JM; Munro A; Cameron DA; Thomas J; Prescott R; Twelves CJ
J Clin Oncol; 2008 Nov; 26(31):5027-35. PubMed ID: 18768436
[TBL] [Abstract][Full Text] [Related]
9. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
10. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
[TBL] [Abstract][Full Text] [Related]
11. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
12. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
13. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
14. DNA repair gene expression and risk of locoregional relapse in breast cancer patients.
Le Scodan R; Cizeron-Clairac G; Fourme E; Meseure D; Vacher S; Spyratos F; de la Lande B; Cvitkovic F; Lidereau R; Bieche I
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):328-36. PubMed ID: 20092964
[TBL] [Abstract][Full Text] [Related]
15. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
Chang HR; Glaspy J; Allison MA; Kass FC; Elashoff R; Chung DU; Gornbein J
Cancer; 2010 Sep; 116(18):4227-37. PubMed ID: 20549829
[TBL] [Abstract][Full Text] [Related]
16. CORRELATION BETWEEN CLINICAL PATHOLOGY OF LUMINAL B BREAST CANCER AND DETERMINATION OF ESTROGEN RECEPTOR, PROGESTERONE RECEPTOR AND HER2 EXPRESSION COMBINED WITH NUCLEAR MORPHOLOGY.
Yin D; Wang YL; Wang YF; Yang L; Zhang L; Tang C; Xie W; Ma Y
J Biol Regul Homeost Agents; 2015; 29(3):579-87. PubMed ID: 26403396
[TBL] [Abstract][Full Text] [Related]
17. Raf kinase inhibitory protein role in the molecular subtyping of breast cancer.
Al-Mulla F; Marafie M; Zea Tan T; Paul Thiery J
J Cell Biochem; 2014 Mar; 115(3):488-97. PubMed ID: 24123286
[TBL] [Abstract][Full Text] [Related]
18. Clinical and pathological response to neoadjuvant chemotherapy based on primary tumor reduction is correlated to survival in hormone receptor-positive but not hormone receptor-negative locally advanced breast cancer.
Chen S; Liu Y; Ouyang QW; Huang L; Luo RC; Shao ZM
Ann Surg Oncol; 2015 Jan; 22(1):32-9. PubMed ID: 25012266
[TBL] [Abstract][Full Text] [Related]
19. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
[TBL] [Abstract][Full Text] [Related]
20. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.
Chia S; Norris B; Speers C; Cheang M; Gilks B; Gown AM; Huntsman D; Olivotto IA; Nielsen TO; Gelmon K
J Clin Oncol; 2008 Dec; 26(35):5697-704. PubMed ID: 19001334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
